Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000 common shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. The common shares are listed on the NASDAQ Global Market under the symbol “ACIU.” 

Based in Lausanne, Switzerland, AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. AC Immune designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Derek Dostal and associates Martin Oberst and Nara Lee. The tax team included partner Michael Mollerus and associate Caroline E. Dayton. The intellectual property and technology team included counsel David R. Bauer and associate Bonnie Chen. The executive compensation team included partner Kyoko Takahashi Lin and associate Abigail Lane. All members of the Davis Polk team are based in the New York office. 

Copy link to share post